Related Experiment Videos
Apolipoprotein E1 Baden (Arg(180)-->Cys). A new apolipoprotein E variant associated with hypertriglyceridemia
M M Hoffmann1, H Scharnagl, W Köster
1Division of Clinical Chemistry, Medical School, Albert Ludwigs-University, Hugstetter Str. 55, D-79106 Freiburg, Germany. mhoff@med1.ukl.uni-freiburg.de
Clinica Chimica Acta; International Journal of Clinical Chemistry
|February 13, 2001
Summary
A newly identified apoE1 Baden mutation (Arg180Cys) is linked to hypertriglyceridemia. This apolipoprotein E variant may impair very low-density lipoprotein triglyceride hydrolysis.
Area of Science:
- Biochemistry
- Genetics
- Lipid Metabolism
Background:
- Apolipoprotein E (apoE) plays a crucial role in clearing lipoprotein remnants from plasma.
- Genetic variations in apoE influence lipoprotein receptor binding and are associated with dyslipidemias like hyperlipoproteinemia (HLP).
- Specific apoE isoforms, such as apoE2, are linked to type III HLP due to defective receptor binding.
Observation:
- A 42-year-old hypertriglyceridemic woman presented with an apoE phenotype of 3/1.
- Genetic analysis revealed a novel mutation, Arg(180)-->Cys, in an apoE epsilon 2 allele, designated apoE1 Baden.
- This mutation altered a HaeII endonuclease recognition site, facilitating rapid screening.
Findings:
- The apoE1 Baden mutation (Arg180Cys) was consistently found in hypertriglyceridemic relatives of the proband.
- The mutation is located within the lipid-binding domain of apolipoprotein E.
- This specific mutation is associated with hypertriglyceridemia.
Implications:
- ApoE1 Baden is a novel genetic variant linked to hypertriglyceridemia.
- The Arg180Cys substitution may cause hypertriglyceridemia by affecting very low-density lipoprotein triglyceride hydrolysis.
- Understanding apoE variants like apoE1 Baden is critical for diagnosing and managing lipid disorders.